Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

[1]  R. Greil,et al.  Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. , 2019, Blood.

[2]  R. Schlenk,et al.  Targeting FLT3 mutations in AML: review of current knowledge and evidence , 2019, Leukemia.

[3]  Tamara J. Blätte,et al.  Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603) , 2018, Blood.

[4]  Z. Estrov,et al.  Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid Leukemia , 2018, American journal of hematology.

[5]  Hong-jie Shen,et al.  Impact of FLT3-ITD length on prognosis of acute myeloid leukemia , 2018, Haematologica.

[6]  W. Hiddemann,et al.  Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia , 2018, Oncotarget.

[7]  C. Bloomfield,et al.  Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study , 2017 .

[8]  F. Appelbaum,et al.  Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  M. Levis,et al.  Midostaurin approved for FLT3-mutated AML. , 2017, Blood.

[10]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[11]  M. Walther,et al.  Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia , 2017, Haematologica.

[12]  R. Hills,et al.  A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. , 2017, Blood.

[13]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[14]  R. Hehlmann.  Faculty Opinions recommendation of Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017 .

[15]  C. Bloomfield,et al.  A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. , 2017, Blood advances.

[16]  T. Naoe,et al.  Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells , 2016, Oncotarget.

[17]  M. Levis,et al.  The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells , 2016, Leukemia.

[18]  S. Armstrong,et al.  Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo , 2016, Leukemia.

[19]  Y. Kim,et al.  Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length , 2015, Blood Cancer Journal.

[20]  M. Konopleva,et al.  The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial , 2014 .

[21]  L. Bullinger,et al.  Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. , 2014, Blood.

[22]  R. Hills,et al.  AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial , 2013 .

[23]  J. Esteve,et al.  Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. , 2013, Blood.

[24]  B. Leber,et al.  A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186 , 2013, Leukemia & lymphoma.

[25]  H. Kantarjian,et al.  Impact of numerical variation in FMS‐like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia , 2012, Cancer.

[26]  T. Grafone,et al.  An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment , 2012, Oncology reviews.

[27]  Kathleen M Murphy,et al.  FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. , 2010, Blood.

[28]  Adam J Mead,et al.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.

[29]  R. Kusec,et al.  More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML). , 2006, Blood.

[30]  Jeremy W. Linsley,et al.  Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. , 2006, Blood.

[31]  F. Lu,et al.  The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. , 2004, Molecular cell.

[32]  Axel Benner,et al.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.

[33]  Martin Dugas,et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .

[34]  G. Ehninger,et al.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. , 2002, Blood.

[35]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[36]  R. Schlenk,et al.  Molecular targets for therapy Targeting FLT 3 mutations in AML : review of current knowledge and evidence , 2019 .

[37]  M. Järvinen,et al.  Biology and Treatment , 2009 .